New research data surrounding the medication Retatrutide , specifically the 120 milligram formulation referred to as ZPHC, reveal a considerable impact on body mass decrease and related health illnesses . Scientists anticipate that this combined compound, targeting both GLP-1 and GIP pathways , has the potential to offer a substantial improvement